Immune mechanisms and possible immune therapy in testicular germ cell tumours
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune mechanisms and possible immune therapy in testicular germ cell tumours
Authors
Keywords
-
Journal
Andrology
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-06-06
DOI
10.1111/andr.12656
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Systemic immune-inflammation index in germ-cell tumours
- (2018) Michal Chovanec et al. BRITISH JOURNAL OF CANCER
- Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy
- (2018) Christian Daniel Fankhauser et al. BRITISH JOURNAL OF CANCER
- Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies.
- (2018) Rosa Maria Nadal et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrated Molecular Characterization of Testicular Germ Cell Tumors
- (2018) Hui Shen et al. Cell Reports
- An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis
- (2018) Andrea Necchi et al. EUROPEAN UROLOGY
- Apache: An open label, randomized, phase 2 study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage.
- (2018) Daniele Raggi et al. JOURNAL OF CLINICAL ONCOLOGY
- Reply to Haffner et al.: DNA hypomethylation renders tumors more immunogenic
- (2018) Meredith L. Stone et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- βcatenin is a marker of poor clinical characteristics and suppressed immune infiltration in testicular germ cell tumors
- (2018) Michal Chovanec et al. BMC CANCER
- Emerging Prognostic Biomarkers in Testicular Germ Cell Tumors: Looking Beyond Established Practice
- (2018) Michal Chovanec et al. Frontiers in Oncology
- Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation
- (2017) Stefanie Zschäbitz et al. EUROPEAN JOURNAL OF CANCER
- Egress of sperm autoantigen from seminiferous tubules maintains systemic tolerance
- (2017) Kenneth S.K. Tung et al. JOURNAL OF CLINICAL INVESTIGATION
- High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience
- (2017) Nabil Adra et al. JOURNAL OF CLINICAL ONCOLOGY
- De-novo and acquired resistance to immune checkpoint targeting
- (2017) Nicholas L Syn et al. LANCET ONCOLOGY
- Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors
- (2017) Michal Chovanec et al. Oncotarget
- An in vitro model demonstrates the potential of neoplastic human germ cells to influence the tumour microenvironment
- (2017) B. Klein et al. Andrology
- Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors
- (2016) S. Zschäbitz et al. ANNALS OF ONCOLOGY
- Specific immune cell and cytokine characteristics of human testicular germ cell neoplasia
- (2016) Britta Klein et al. HUMAN REPRODUCTION
- Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality
- (2016) Asim Saha et al. JOURNAL OF CLINICAL INVESTIGATION
- Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine
- (2016) Costantine Albany et al. Oncotarget
- Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors
- (2015) Z. Cierna et al. ANNALS OF ONCOLOGY
- The Mammalian Blood-Testis Barrier: Its Biology and Regulation
- (2015) Dolores D. Mruk et al. ENDOCRINE REVIEWS
- Antibodies regulate antitumour immunity
- (2015) Laurence Zitvogel et al. NATURE
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Testicular defense systems: immune privilege and innate immunity
- (2014) Shutao Zhao et al. Cellular & Molecular Immunology
- Testicular Cancer — Discoveries and Updates
- (2014) Nasser H. Hanna et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemoimmunotherapy: reengineering tumor immunity
- (2013) Gang Chen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- Phenotypic characterisation of immune cell infiltrates in testicular germ cell neoplasia
- (2013) Tine Hvarness et al. JOURNAL OF REPRODUCTIVE IMMUNOLOGY
- Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo
- (2012) Connie Jackaman et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Regulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective
- (2012) D. T. Le et al. CANCER RESEARCH
- A Landscape of Driver Mutations in Melanoma
- (2012) Eran Hodis et al. CELL
- Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cellsin vitroin a TLR4-independent manner
- (2012) Tillmann Michels et al. Journal of Immunotoxicology
- Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer Cells
- (2012) Shan Wan et al. PLoS One
- Structural, cellular and molecular aspects of immune privilege in the testis
- (2012) Nan Li et al. Frontiers in Immunology
- B7-H1 Expressed by Activated CD8 T Cells Is Essential for Their Survival
- (2011) V. Pulko et al. JOURNAL OF IMMUNOLOGY
- The growing diversity and spectrum of action of myeloid-derived suppressor cells
- (2010) Alberto Mantovani EUROPEAN JOURNAL OF IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation